This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Sumitomo Dainippon Pharma Co., Ltd.
Drug Names(s): AVE-3933, Radequinil
Description: AC-3933 is a novel cognitive enhancer, with central benzodiazepine receptor (GABA-A receptor) partial inverse agonist properties. AC-3933 suppresses the GABA neurons that inhibit the cholinergic neurons, resulting in the activation of cholinergic neurons. The drug may activate glutamate neurons, as well.
Deal Structure: In August 2003, Dainippon concluded an agreement to license AC-3933 to Aventis. Under this agreement, Aventis will receive the exclusive development and marketing rights of AC-3933 for the world, except Japan, with option rights for China, Taiwan and South Korea. The license to AC-3933 was returned to Dainippon in 2005.
Additional information available to subscribers only: